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Abstract 
Background: Severe malaria remains a major cause of childhood mortality globally. Decreased endothelial nitric 
oxide is associated with severe and fatal malaria. The hypothesis was that adjunctive inhaled nitric oxide (iNO) would 
improve outcomes in African children with severe malaria.
Methods: A randomized, blinded, placebo-controlled trial of iNO at 80 ppm by non-rebreather mask versus room air 
placebo as adjunctive treatment to artesunate in children with severe malaria was conducted. The primary outcome 
was the longitudinal course of angiopoietin-2 (Ang-2), an endothelial biomarker of malaria severity and clinical 
outcome.
Results: One hundred and eighty children were enrolled; 88 were assigned to iNO and 92 to placebo (all received 
IV artesunate). Ang-2 levels measured over the first 72 h of hospitalization were not significantly different between 
groups. The mortality at 48 h was similar between groups [6/87 (6.9 %) in the iNO group vs 8/92 (8.7 %) in the pla-
cebo group; OR 0.78, 95 % CI 0.26–2.3; p = 0.65]. Clinical recovery times and parasite clearance kinetics were similar 
(p > 0.05). Methaemoglobinaemia >7 % occurred in 25 % of patients receiving iNO and resolved without sequelae. 
The incidence of neurologic deficits (<14 days), acute kidney injury, hypoglycaemia, anaemia, and haemoglobinuria 
was similar between groups (p > 0.05).
Conclusions: iNO at 80 ppm administered by non-rebreather mask was safe but did not affect circulating levels of 
Ang-2. Alternative methods of enhancing endothelial NO bioavailability may be necessary to achieve a biological 
effect and improve clinical outcome.
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Background
Severe malaria due to Plasmodium falciparum claims 
0.6–1.2 million lives annually, 86 % of whom are children 
in sub-Saharan Africa [1, 2]. Despite the use of highly 
effective anti-malarial medications, 10–30  % patients 
with severe malaria will die [3], highlighting the need 
for new adjunctive therapy. Nitric oxide (NO), with its 
modulating effects on host endothelial activation, is a 
promising agent based on pre-clinical findings and an 
established safety profile in clinical practice [4, 5].
NO is a gaseous, lipid-soluble, free radical, endoge-
nously produced from l-arginine and molecular oxygen 
by members of the nitric oxide synthase family [6]. NO 
regulates a broad range of physiologic and pathologic 
processes, including vasodilation, platelet aggregation, 
apoptosis, inflammation, chemotaxis, neurotransmission, 
antimicrobial defence, and endothelial activation [6].
The vascular endothelium plays a central role in the 
pathogenesis of severe malaria. Parasitized erythrocytes 
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(PEs) adhere to the endothelial cells via constitutive and 
cytokine-inducible receptors. NO decreases endothelial 
cell adhesion molecule expression, and has been shown to 
reduce the adherence of PEs to endothelial cells [7]. Upon 
activation, endothelial cells release angiopoietin-2 (Ang-
2) from intracellular Weibel-Palade bodies (WPB) storage 
granules [8]. Ang-2 functions as an autocrine regulator 
by sensitizing the endothelium to the effects of tumour 
necrosis factor, resulting in increased adhesion receptor 
expression [9]. Ang-2 is associated with malarial retin-
opathy and is an independent and quantitative marker of 
disease severity and clinical outcome in malaria [10–12]. 
Ang-2 has also been used to follow disease progression 
and recovery in previous studies of malaria [13]. NO 
inhibits the exocytosis of WPB contents through S-nitros-
ylation of critical regulatory proteins [14].
Reduced bioavailability of NO contributes to the 
pathogenesis of severe malaria. African children with 
severe malaria have impaired production of NO [15] 
and low plasma arginine levels [16], the substrate for NO 
synthesis. Treatment of Indonesian adults with severe 
malaria with intravenous l-arginine increased levels of 
exhaled NO, and reversed malaria-associated endothe-
lial dysfunction [17]. Pathways of endothelial activation 
and dysfunction are reflected in experimental models of 
severe malaria, where inhaled NO enhances endothelial 
integrity, reduces parasite accumulation in the brain vas-
culature, and improves survival [5, 18].
Administration of exogenous NO at 5–80  ppm is 
approved for use by the US FDA for neonates with 
hypoxic respiratory failure [19].Inhaled nitric oxide 
(iNO) has been safely used in clinical practice and in 
large clinical trials involving critically ill neonates [19], 
as well as in children and adults with refractory hypoxia 
[20]. Adverse effects attributable to iNO in these studies 
are rare and include methaemoglobinaemia, renal insuf-
ficiency [21] and hypotension.
To test the hypothesis that iNO would improve out-
comes in children with severe malaria, a randomized, 
blinded, controlled trial was conducted. The primary 
objective was to determine if iNO at 80 ppm, relative to 
placebo room air, would improve endothelial function 
as determined by an accelerated rate of decline of Ang-2 




This was a prospective, parallel arm, randomized, pla-
cebo-controlled, blinded trial of iNO versus placebo (1:1 
ratio), among children with severe malaria, all of whom 
were treated with artesunate. The trial protocol has been 
described in detail previously [22].
Ethics, consent and permissions
The study was reviewed and approved by the Makerere 
University School of Medicine Research Ethics Com-
mittee (REC Protocol # 2010-107), the Uganda National 
Council on Science and Technology (Ref: HS 857), the 
National Drug Authority of Uganda (Ref: 297/ESR/
NDA/DID-01/2011), and the University Health Network 
Research Ethics Committee, Toronto, Canada (UHN REB 
Number 10-0607-B). A data and safety monitoring board 
(DSMB) was convened and met periodically to review 
trial quality and adverse events. An interim analysis at 
the trial midpoint was conducted to review trial quality 
and safety, at which time the DSMB recommended that 
the trial proceed without modifications. The trial is regis-
tered (ClinicalTrials.gov Identifier: NCT01255215).
Setting and participants
The trial was conducted at a single centre, the Jinja 
Regional Referral Hospital, in Uganda. Malaria transmis-
sion is moderate and seasonal in Jinja and the surround-
ing Busoga catchment area [23]. The hospital operates 
under severe resource constraints, and over 30  % of all 
admissions are due to malaria.
Children (age 1–10  years) were included if they had 
a positive rapid diagnostic test for both P. falciparum 
histidine rich protein 2 (HRP2) and lactate dehydroge-
nase (pLDH)(First Response Malaria Ag. (pLDH/HRP2) 
Combo Rapid Diagnostic Test, Premier Medical Corpo-
ration Limited, India) [24], as well as selected criteria for 
severe malaria: repeated seizures (two or more general-
ized seizures in 24  h), prostration, impaired conscious-
ness (Blantyre Coma Score <5), respiratory distress 
(age-related tachypnea with sustained nasal flaring, deep 
breathing or sub-costal retractions). Patients were not 
included if they had methaemoglobin (metHb) >2  % at 
baseline, known chronic illness (renal, cardiac or hepatic 
disease, diabetes, epilepsy, cerebral palsy, or AIDS), 
severe malnutrition (weight-for length or height below 
−3 standard deviations based on WHO reference charts, 
or symmetrical oedema involving at least the feet). Modi-
fications to the exclusion criteria were made with regu-
latory committee approval after experience with the first 
20 enrolled participants. The following exclusion criteria 
were added: haemoglobinopathy, clinical suspicion of 
acute bacterial meningitis, unlikely to tolerate mask for 
study gas delivery, and prior quinine in the emergency 
department. Trial nurses or clinicians from the emer-
gency department screened patients for eligibility using 
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a uniform checklist and clinicians made final decisions 
about inclusion in the study.
Randomization and blinding
In order to blind clinicians, nurses, parents, and partici-
pants to treatment while titrating and monitoring con-
centrations of iNO and dose-related levels of metHb and 
NO2, a dedicated unblinded team was used, the members 
of which were not involved in clinical care decisions or 
outcome assessments.
Eligible patients were randomly assigned to treat-
ment with either iNO or room air placebo (both arms 
received intravenous artesunate). Simple randomization 
was employed, using a computer-generated list created 
by unblinded team leader (AC) prior to trial commence-
ment. Treatment assignment was recorded on paper and 
kept in sequentially numbered, sealed, opaque enve-
lopes in a locked cabinet accessible only to the unblinded 
study team. After patient stabilization and informed 
consent, the next envelope was drawn by an unblinded 
investigator.
iNO was indistinguishable from room air in colour 
and delivery apparatus (mask, tubing, a stream of vehi-
cle air). An unblinded team member initiated the study 
gas while treating nurses and clinicians were out of the 
room. Flowmeters and monitoring devices were in locked 
opaque boxes accessible only to the unblinded study 
team. MetHb measurements were performed using non-
invasive pulse CO-oximetry (Masimo Rad-57™, Masimo 
Corporation, Irvine, CA, USA) by unblinded study team 
members. All laboratory assays and statistical analyses 
were performed blinded to treatment allocation.
Procedures
iNO was delivered continuously at a target concentration 
of 80 ppm by non-rebreather mask for up to 72 h. An air 
compressor was used to deliver continuous flow of vehicle 
air, and NO from compressed cylinders was titrated into 
the air stream to a concentration of 80  ppm, measured 
continuously at the bedside using a NO-NO2 analyser 
(Pulmonox Sensor; Pulmonox Research and Development 
Corporation, Tofield, Alberta, Canada). Methaemoglobi-
naemia and inspired NO2 were monitored at least every 
4 h. The concentration of iNO administered was adjusted 
downward if the metHb level in peripheral blood rose 
above 7 %, and was temporarily discontinued for metHb 
>10  %. Participants in the control group received room 
air by non-rebreather mask. Both groups received intra-
venous artesunate, the recommended first-line treatment 
for severe malaria, at recommended dose and frequency 
[25]. Follow-on oral therapy was with artemether-lume-
fantrine tablets or suspension for 3 days.
Bloodwork for clinical and study purposes was drawn 
at admission and daily during the first 72  h of hospital 
admission. Admission venous blood samples were ana-
lysed at the bedside for haematocrit, creatinine, lactate, 
and glucose [26] and at a central laboratory for parasite 
density, as previously described [24]. Lumbar puncture 
was performed at the clinician’s discretion and was ana-
lysed for cell count and differential, total protein, Gram 
stain and bacterial culture.
Study outcomes
The analysis was undertaken according to a pre-spec-
ified analytical plan [22]. There were no changes to any 
trial outcomes after the trial commenced. The primary 
endpoint was the longitudinal serum Ang-2 concentra-
tion over the first 72 h of hospital admission. Ang-2 was 
measured from serum samples using commercially avail-
able enzyme-linked immunosorbent assay (ELISA) kits 
(DuoSets, R&D Systems, Minneapolis, MN, USA).
Secondary trial outcomes included: mortality, recov-
ery times, parasite clearance kinetics, and safety. Adverse 
events were monitored daily using paediatric toxicity 
tables modified from the US National Institute of Allergy 
and Infectious Diseases [27].
Statistical analysis
Inclusion of 180 children with severe malaria was needed 
to show, with 80  % power and 95  % confidence, a 50  % 
difference in the rate of change of Ang-2. This calcula-
tion was supported by a simulation study under various 
assumptions of variance and treatment effect [22].
The primary outcome, longitudinal course of Ang-2, 
was compared between study arms using linear mixed-
effects (LME) models. All available data was used for the 
primary analysis. Because of (non-random) missing lon-
gitudinal data due to death, withdrawal and lost samples, 
sensitivity analyses were performed with different meth-
ods of adjusting for missing data (‘intention-to-treat’ 
analysis), as outlined in Additional file  1. Model fit was 
assessed by visual inspection of residuals.
For secondary binary outcomes, Chi squared or Fisher 
exact test were used, as appropriate. Time to event out-
comes were compared with the log-rank test, and hazard 
ratios (HRs) together with 95 % CIs were estimated by a 
Cox proportional hazard model.
Statistical analyses were done with SPSS (version 16.0) 
and R (version 3.0.1).
Role of the funding source
The sponsor of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report.
Page 4 of 11Hawkes et al. Malar J  (2015) 14:421 
Results
Figure  1 shows the trial profile. Recruitment occurred 
between 12 July, 2011 and 14 June, 2013, with last follow-
up visit on 28 June, 2013. The trial ended when the pre-
specified sample size was reached.
No significant differences in baseline characteris-
tics between the two treatment groups were observed 
(Table  1). Ten patients were positive for both HRP2 
and pLDH bands on screening rapid diagnostic test but 
negative on microscopy of the admission sample. One 
additional patient had a microscopist diagnosis of Plas-
modium ovale. All these samples tested positive for P. 
falciparum by PCR. These cases were equally distributed 
between groups (5/88 (5.7 %) iNO and 6/92 (6.5 %) pla-
cebo, p  =  1.0). No alternative diagnosis was apparent 
(blood culture negative in all cases) and two patients with 
negative microscopy died.
Fig. 1 Trial profile. RDT rapid diagnostic test, Ang-2 angiopoietin-2, LME linear mixed effects
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Table 1 Baseline characteristics of the two treatment groups
iNO (N = 88) Placebo (N = 92)
Female sex 35 (40 %) 43 (47 %)
Age (years), median (IQR) 2.0 (1.0–3.0) 2.0 (1.0–3.0)
Fever before enrolment (days), median (IQR) 3 (2–4) 3 (2–4)
Coma before enrolment (hours), median (IQR) 8.0 (3.0–11) 5.0 (2.0–15)
Pretreatment with anti-malarials
 None 36 (41 %) 42 (46 %)
 Ineffectivea 5 (6 %) 1 (1 %)
 Effectivea 47 (53 %) 49 (53 %)
Complications on admission
 Coma 54 (61 %) 52 (57 %)
 Convulsions 69 (78 %) 75 (82 %)
 Jaundice 13 (15 %) 15 (16 %)
 Severe anaemia (haemoglobin <50 g/L) 44 (50 %) 51 (55 %)
 Shock 9 (10 %) 12 (13 %)
 Hypotensive shock 1 (1 %) 1 (1 %)
 Severe acidosis (BE <−8 mmol/L) 36 (50 %) 33 (44 %)
 Hypoglycaemia (<3 mmol/L) 4 (5 %) 7 (8 %)
 Respiratory distressb 50 (57 %) 46 (50 %)
 Prostration 78 (89 %) 86 (93 %)
 Haemoglobinuria 18 (21 %) 16 (17 %)
 Hyperparasitaemia (>10 %) 10 (11 %) 7 (8 %)
Clinical examination
 Weight (kg), mean (SD) 11.5 (3.7) 11.7 (3.6)
 Temperature (°C), mean (SD) 38.0 (1.2) 37.9 (1.1)
 Blood pressure (mm Hg)
  Systolic, mean (SD) 108 (20) 113 (20)
  Diastolic, mean (SD) 58 (14) 60 (13)
  Blantyre coma score, median (IQR) 2 (2–3) 2 (2–3)
Co-morbidity
 HIV 4 (5 %) 1 (1 %)
 Suspected pneumoniac 8 (9 %) 12 (13 %)
 Clinical sepsisd 27 (31 %) 28 (30 %)
 Suspected meningitise 4 (5 %) 1 (1 %)
Laboratory assessments
 Parasitaemia (parasites per μL), geometric mean (range)f 15,700 (0–696,000) 19,300 (0–316,000)
 Sodium (mmol/L), mean (SD) 139 (5.0) 137 (4.6)
 Potassium (mmol/L), mean (SD) 4.2 (0.6) 4.1 (0.6)
 Chloride (mmol/L), mean (SD) 110 (6) 107 (5)
 Creatinine (umol/L), mean (SD) 44 (33) 36 (27)
 Haemoglobin (g/L), mean (SD) 61 (24) 62 (27)
 pH, mean (SD) 7.37 (0.12) 7.38 (0.11)
 PaCO2 (mm Hg), mean (SD) 28.0 (10.2) 28.1 (7.5)
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The median (IQR) linear rate of change of Ang-2 
over the first 72  h of hospitalization was −2.1 (−3.1 to 
−1.2)  ng/mL/day in patients receiving iNO vs −1.9 
(−3.6 to −0.57) ng/mL/day in patients receiving placebo 
(p = 0.68). A LME model did not show a statistically sig-
nificant effect of iNO on the rate of change of Ang-2 over 
time (p = 0.72). Figure 2a, b shows the Ang-2 levels over 
time for patients in the iNO and placebo groups, together 
with best fit curve from the LME model.
Mortality outcomes (Table  2) and survival curves 
(Fig.  2c) show that most deaths occurred within 48  h 
of admission and occurred at similar frequency in both 
groups. Incidence of complications during hospitaliza-
tion (development of coma, deterioration of coma score, 
new or persistent seizures, hypoglycaemia, development 
of severe anaemia, and haemoglobinuria) was also simi-
lar between groups (Table  2). Ang-2 levels were higher 
at admission among patients who subsequently died 
compared to survivors (median (IQR) 20 (8.8–29)  ng/
mL among fatal cases vs 8.9 (4.9–14) ng/mL among sur-
vivors; p  =  0.0068). Co-treatments, administered by 
physicians blinded to randomization arm, were similar 
Fig. 2 Primary biochemical trial endpoint and mortality. Longitudinal Ang-2 concentrations in treatment (iNO) and control (room air) groups did 
not differ significantly (p = 0.72, a and b). Solid black dots (indicating survivors), red circles (non-survivors), and best-fit curve from a LME model are 
shown. Survival curves were not significantly different between groups (p = 0.67, c)
Data are number (%), unless otherwise indicated
SD standard deviation, IQR interquartile range, BE base excess, PaCO2 partial pressure of carbon dioxide, HCO3 bicarbonate
a Classification of anti-malarial effectiveness followed AQUAMAT [25]. The following were considered effective: quinine injection, artemether injection, artesunate/
artemether tabs, artemether-lumefantrine, artesunate suppository, artesunate-amodiaquine, artemether-amodiaquine, artemether-quinine, dihydroartemisinin 
(DHA), DHA-amodiaquine, and SP-artemether-lumefantrine. The following were considered intermediate or ineffective: sulfadoxine-pyrimethamine (SP), 
SP-amodiaquine, chloroquine, amodiaquine, and pyrimethamine-sulphamethopirazine
b Respiratory distress was defined as nasal alar flaring, costal indrawing, or deep breathing
c Pneumonia was diagnosed on clinical grounds (chest radiographs were not performed routinely). Fast breathing and fever were signs used to make a diagnosis of 
pneumonia
d Blood cultures were positive in 2/88 (2.3 %) iNO group and 8/91 (8·8 %) placebo: 6 coagulase-negative staphylococcus (likely contaminants); 2 Staphylococcus 
aureus; and 2 coliform Gram-negative organism. Of note, antibiotics had been given prior to venipuncture for blood culture in almost all cases
e Lumbar puncture was performed in 23/88 (26 %) iNO group and 28/92 (30 %) placebo. CSF culture was negative in all patients but one, which grew mixed Gram 
positive and Gram-negative organisms (likely contamination). The CSF leukocyte count was <5 cells/mm3 in all but one patient, who had 35 cells (predominantly 
lymphocytes) and negative blood culture
f In 10 cases, no parasites were seen on the admission blood smear, despite a positive screening RDT result. In one other case, the species was diagnosed as P. ovale. In 
all of these cases, PCR performed on the red blood cell pellet was positive for P. falciparum [24]
iNO (N = 88) Placebo (N = 92)
 HCO3 (mmol/L), mean (SD) 10.0 (11.6) 10.7 (12.0)
 Plasma BE (mmol/L), mean (SD) −2.8 (12.7) −2.5 (12.2)
Table 1 continued
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between groups, with the exception of anticonvulsants 
(Table 2). In particular, the use of antibiotics was not sta-
tistically significantly different between groups (82/87 
(94 %) iNO and 80/91 (88 %) placebo, p = 0.19).
Among survivors, the recovery times (time to eat, sit 
unsupported, localize pain, fever resolution, recovery 
of consciousness, and discharge) were similar between 
groups (Table  3). Parasite clearance kinetics with 
Table 2 Mortality, complications and co-treatments according to treatment group
OR odds ratio
a Strictly defined severe malaria as in AQUAMAT [25]. At least one of the following criteria was required: plasma base excess <–3.3 mmol/L; Blantyre coma scale <3/5; 
haemoglobin <50 g/L and parasitaemia >100,000 parasites/μL; compensated shock (capillary refill ≥3 s but no hypotension); decompensated shock (systolic blood 
pressure <70 mmHg and cool peripheries); asexual parasitaemia >10 %; visible jaundice and >100,000 parasites/μL; plasma glucose <3 mmol/L; respiratory distress 
(defined as costal indrawing, use of accessory muscles, nasal alar flaring, or deep breathing)
b Strictly defined cerebral malaria required Blantyre coma scale <3, exclusion of hypoglycaemia and post-ictal state as the cause of coma
c Development of coma, anaemia and haemoglobinuria was assessed only in patients without these disorders on admission
iNO (n/N, %) Placebo (n/N, %) OR (95 % CI) p value
Mortality
 Mortality, 48 h 6/87 (6.9 %) 8/92 (8.7 %) 0.78 (0.26–2.3) 0.65
 Mortality, in hospital 7/87 (8.0 %) 8/92 (8.7 %) 0.92 (0.32–2.7) 0.88
 Mortality, 14 days 7/87 (8.0 %) 9/91 (9.9 %) 0.80 (0.28–2.2) 0.67
 Death or sequelae at 14 days 12/87 (13 %) 16/91 (14 %) 0.75 (0.33–1.7) 0.75
 Mortality in strictly defined severe malariaa 7/81 (8.6 %) 9/88 (10 %) 0.83 (0.29–2.3) 0.73
 Mortality in strictly defined cerebral malariab 6/53 (11 %) 8/51 (16 %) 0.69 (0.22–2.1) 0.51
 Mortality in HIV 1/4 (25 %) 0/1 (0 %) – 1.0
Complications
 Development of comac 2/26 (7·7 %) 0/34 (0 %) – 0.18
 Deterioration of coma score 8/86 (9·3 %) 5/91 (5·5 %) 1·8 (0·55–5·6) 0.33
 Convulsions developing or persisting >6 h after admission 19/87 (22 %) 13/91 (14 %) 1.7 (0·77–3·6) 0.19
 Hypoglycaemia (<3 mmol/L) 10/88 (10 %) 17/91 (19 %) 0.56 (0·24–1·3) 0.12
 Severe anaemia (<50 g/L) after admissionc 11/35 (31 %) 5/34 (15 %) 2·7 (0.81–8.7) 0.10
 Haemoglobinuriac 0/68 (0 %) 3/76 (3.9 %) 0 (0–3.6) 0.25
Co-treatments
 Blood transfusion 65/87 (75 %) 67/91 (74 %) 1.1 (0.54–2.1) 1.0
 Intravenous fluids 80/88 (91 %) 82/91 (90 %) 1.1 (0.40–3.0) 1.0
 Antibiotics (any) 82/87 (94 %) 80/91 (88 %) 2.3 (0.75–6.8) 0.19
 Ceftriaxone 81/87 (93 %) 76/91 (84 %) 2.7 (0.98–7.2) 0.06
 Anticonvulsant (any) 51/87 (59 %) 36/91 (40 %) 2.2 (1.2–3.9) 0.016
 Diazepam 40/87 (46 %) 27/91 (30 %) 2.0 (1.1–3.7) 0.030
 Phenobarbitone 29/87 (33 %) 23/91 (25 %) 1.5 (0.77–2.8) 0.25
 Antipyretic (any) 64/87 (74 %) 71/91 (78 %) 0.78 (0.39–1.6) 0.60
Table 3 Recovery times in surviving patients according to treatment group
IQR inter-quartile range, HR hazard ratio
iNO (N = 80) (median, IQR) Placebo (N = 83) (median, IQR) HR (95 % CI) p value
Time to discharge (days) 4.0 (3.0–4.0) 3.0 (3.0–4.0) 1.1 (0.83–1.6) 0.40
Time to eat (h) 17 (7–37) 10 (6–23) 1.3 (0.92–1.7) 0.15
Time to sit unsupported (h) 41 (20–75) 28 (13–60) 1.3 (0.98–1.8) 0.063
Time to localize pain (h) 5 (0–11) 2 (0–9.6) 1.2 (0.84–1.6) 0.38
Time to fever resolution (h) 6 (0–31) 6 (0–23) 1.1 (0.78–1.4) 0.73
Time to recovery of consciousness (h) 14 (6–36) 9 (4–19) 1.2 (0.90–1.7) 0.19
Time to 50 % parasite clearance (h) 12 (9–16) 12 (9–18) 0.87 (0.63–1.2) 0.37
Time to 90 % parasite clearance (h) 19 (12–37) 20 (14–37) 0.85 (0.62–1.2) 0.31
Time to parasite clearance (h) 44 (35–63) 44 (37–63) 0.97 (0.71–1.3) 0.83
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artesunate were unaffected by iNO (Table  3). No para-
site recrudescence or re-infection was detected at day 14 
follow-up in either group. At the time of discharge, 5/88 
(5.7 %) iNO recipients and 8/92 (8.7 %) placebo recipients 
had neurologic deficits, including inability to sit, spastic 
or flaccid paresis of one or more limbs, seizures, unilateral 
weakness, vision loss, gaze palsy, and poor head control.
Adverse events were systematically recorded using 
standardized tables on a daily basis in all patients 
(Table 4). The study gas was temporarily or permanently 
discontinued in 19/88 (22  %) iNO patients vs 12/92 
(13 %) placebo (p = 0.13) for reasons shown in Table 5. In 
5/88 (5.7 %) patients receiving iNO, study gas was tempo-
rarily discontinued because of elevated metHb levels. In 
all cases, iNO was resumed after metHb levels declined 
and iNO therapy did not need to be permanently 
discontinued in any patient due to recurrent or refractory 
methaemoglobinaemia. The study gas did not need to be 
titrated downward or discontinued in any patient for ele-
vated inhalational levels of NO2.
Evaluation of the quality of blinding and indices of the 
quality of clinical care provided in the trial are provided 
in Additional file 1.
Discussion
iNO at 80 ppm (iNO80) by non-rebreather mask was safe 
but did not accelerate the decline in circulating Ang-2 
levels during the first 72 h of hospitalization in this study 
of African children with severe malaria. No differences in 
clinical outcomes (e.g., mortality, recovery times) were 
observed, likely because a measurable biological effect 
on the endothelium was not achieved with this dose and 
route of administration of NO. Of note, parasite clear-
ance under artesunate treatment was not affected by the 
addition of iNO.
Among survivors of severe malaria in this study, the 
rate of change of Ang-2 over the first 72  h of hospitali-
zation was −2.2  ng/mL/day (iNO group) and −1.9  ng/
mL/day (placebo group), very similar to that observed in 
a study involving Indonesian adults, at −2.7  ng/mL/day 
[13]. Among four patients who died but had repeated 
measurements of Ang-2, the level increased on average 
by +15 ng/mL/day, compared to +9.5 ng/mL/day in the 
study from Indonesia [13]. Moreover, elevated Ang-2 lev-
els at admission were strongly predictive of mortality in 
this study and in several previous reports from several 
populations [12, 26, 28, 29]. These findings lend further 
validity to Ang-2 as a clinically informative biomarker 
for prognosis in children with severe malaria that can be 
used to follow the course of disease progression and as a 
surrogate endpoint for severe malaria studies.
In-hospital mortality was similar in the present trial 
to the largest published clinical trial of paediatric severe 
malaria to date, AQUAMAT [25]. In the placebo arm of 
the present trial (patients receiving artesunate alone) the 
mortality was 8.7 %, compared to 8.5 % in the artesunate 
arm of AQUAMAT. Mortality was similar despite evi-
dence that patients in the present trial had more severe 
disease at presentation: 57 vs 32 % coma; 82 vs 30 % con-
vulsions; 55 vs 30 % severe anaemia; 50 vs 16 % respira-
tory distress; 93 vs 62 % severe prostration, in the placebo 
arm of the present trial vs artesunate arm of AQUAMAT, 
respectively [25]. The clinical care in the present trial 
(see Additional file  1) was superior to that provided at 
Uganda’s national referral hospital by several indices: (1) 
77 vs 23  % were seen by a clinician within one hour of 
presentation; (2) 68 vs 12 % received the first dose of anti-
malarial drug within 2 h of presentation; (3) no missing 
supplies and two instances of lack of blood in the hospital 
Table 4 Adverse events according to treatment group
a Elevated creatinine was defined as follows: For children age 1 to <2 years 
old, grade 1: 0.6–0.89 × upper limit of normal (ULN); grade 2: 0.9–1.19 × ULN; 
grade 3: 1.2–1.5 × ULN, grade 4: >1.5 × ULN. For children 2–10 years old, grade 
1: 0.7–1.0 × ULN; grade 2: 1.1–1.6 × ULN; grade 3: 1.7–2.0 × ULN, grade 4: 
>2.0 × ULN [27]
b Acute kidney injury was defined as follows: Serum creatinine >1.5 × ULN 
(children age 1–2) or >2.0 × ULN (age 2–10) AND an abrupt (within 48 h) 
reduction in kidney function: (1) an absolute increase in serum creatinine of 
≥26.4 μmol/l; or (2) a percentage increase in serum creatinine of ≥50 % [32]
Adverse event iNO (n/N, %) Placebo (n/N, %) p value
Hyperglycaemia 
(> 6.8 mmol/L)
34/88 (39) 29/92 (32) 0.32
Hypoglycaemia  
(< 3 mmol/L)
5/88 (5.7) 2/92 (2.2) 0.27
Elevated creatinine 30/88 (34) 24/92 (26) 0.26
 Grade 1a 8/88 (9.1) 8/92 (8.8) 1.0
 Grade 2a 11/88 (13) 10/92 (11) 0.82
 Grade 3a 3/88 (3.4) 3/92 (3.3) 1.0
 Grade 4a 8/88 (9.1) 3/92 (3.3) 0.13
 Acute kidney injuryb 7/88 (8.0) 3/92 (3.3) 0.21
Hypotension 0 0 –
Anaemia 9/88 (10) 6/92 (6.6) 0.38
IV Site oedema or induration 17/88 (19) 10/92 (11) 0.12
Peri-orbital oedema 17/88 (19) 4/92 (4.4) 0.002
Vomiting 4/88 (4.5) 4/92 (4.4) 1.0
Conjunctivitis 1/88 (1.1) 1/92 (1.1) 1.0
Diarrhoea 5/88 (5.7) 4/92 (4.4) 0.74
Fever 4/88 (4.5) 5/92 (5.4) 1.0
Cough 5/88 (5.7) 5/92 (5.4) 0.94
Stridor 0 2/92 (2.2) 0.50
Cellulitis 4/88 (4.5) 1/92 (1.1) 0.20
Headache 0 1/92 (1.1) 1.0
Jaundice 1/88 (1.1) 3/92 (3.3) 0.62
Other 14/88 (16) 7/92 (7.7) 0.11
Withdrawal of study gas 19/88 (22) 13/92 (14) 0.13
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compared to 50  % lacking an essential drug or supply 
needed for resuscitation; (4) 92 vs 29 % highest parental 
satisfaction rating with medical care [30].
Safety was objectively and blindly assessed using stand-
ardized toxicity tables. The only clinical sign that dif-
fered between patients receiving iNO80 and placebo was 
peri-orbital oedema, which resolved without discon-
tinuation of study gas. Increased interstitial fluid may 
be most evident in the loose areolar tissue around the 
eye in a recumbent patient, and may indicate transient 
alterations in vascular permeability [although there was 
no difference in Ang-2 levels), renal dysfunction with 
fluid retention (although was no difference in creatinine 
and rates of acute kidney injury (AKI)], or other revers-
ible disturbances of capillary hydrostatic or oncotic 
pressures. As expected, levels of metHb rose in patients 
receiving iNO80. These levels could be controlled with 
downward titration of the study gas and required tem-
porary discontinuation of iNO in only 5.7 % of patients. 
This dose-dependent adverse event provided evidence of 
biological activity of the administered therapy to alter the 
redox state of circulating haemoglobin, although an effect 
on the endothelium was not observed, based on Ang-2 
measurements. AKI was identified as a toxicity of iNO in 
a meta-analysis pooling data from multiple randomized 
trials involving mostly adult patients, although this effect 
was not evident in individual studies [21]. The rate of AKI 
among patients in the present study was 8.0 % in the iNO 
compared to 3.3  % in the placebo group, which did not 
represent a statistically significant difference, although 
the present trial, like former randomized controlled tri-
als of iNO, may have been underpowered to detect small 
differences in AKI rates. Co-treatment with diazepam 
for acute seizure management was statistically more fre-
quent among patients receiving iNO. The significance of 
this finding is unclear since the proportion of patients 
with new onset or persistent seizures, frequency of neu-
rologic sequelae, and time to recovery of consciousness 
was similar to placebo recipients.
Efficacy of iNO80 in a murine model of experimental 
cerebral malaria did not translate to efficacy in humans 
in this clinical trial; however, pre-clinical data from this 
model were critical for generating the hypothesis and 
designing the trial. In mice, unlike humans, iNO altered 
Ang-2 levels, decreased blood–brain barrier dysfunction, 
decreased brain accumulation of parasites, and improved 
survival [5]. Inter-species differences in iNO80 pharma-
cokinetics may account for lack of efficacy in the pre-
sent trial. Rapid conversion of iNO to nitrate and other 
stable adducts may have reduced bioavailable NO at the 
endothelium. On the other hand, iNO has been shown 
to exert pharmacological effects beyond the pulmonary 
vasculature in other studies in humans [31]. Although no 
evidence of efficacy of iNO80 was observed, other doses, 
routes of administration or NO donor molecules remain 
viable options for future investigation. Likewise, the 
Table 5 Study gas discontinuation according to treatment group
a Some children who regained consciousness before 72 h had elapsed on study gas did not tolerate wearing a non-rebreather mask. The study gas was discontinued 
early at the investigator’s or the child/parent’s discretion in these cases
Adverse event iNO (n/N, %) Placebo (n/N,  %) p value
Temporary discontinuation 7/88 (8.0) 3/92 (3.3) 0.21
 Methaemoglobinaemia 5/88 (5.7) 0 0.026
 Elevated inspired NO2 concentration 0 0 –
 Persistent hypoxaemia 0 0 –
 Evolving respiratory distress 0 0 –
 Unexplained tachycardia 1/88 (1.1) 0 0.49
 Unexplained hypotension 0 0 –
 Subject or guardian’s discretion 0 0 –
 Investigator’s discretion 1/88 (1.1) 3/92 (3.3) 0.62
Permanent discontinuation 12/88 (14) 10/92 (11) 0.57
 Refractory methaemoglobinaemia 0 0 –
 Haemoptysis 0 0 –
 Acute kidney injury 7/88 (8.0) 3/92 (3.3) 0.21
 Adverse event that repeats upon re-challenge 0 0 –
 Subject or guardian’s discretiona 4/88 (4.5) 4/92 (4.3) 1.0
 Investigator’s discretiona 1/88 (1.1) 2/92 (2.2) 1.0
 Death (48 h) 6/88 (6.8) 8/92 (8.8) 0.62
 Death (Day 14) 7/88 (8.0) 9/92 (9.9) 0.65
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Ang-Tie2 pathway remains a valid target for experimental 
interventions, and the pre-clinical murine model remains 
a useful tool to test novel therapy in vivo prior to clinical 
trials.
Conclusions
Attempts to find host-directed treatments for severe 
malaria over the past several decades have not yet yielded 
an effective adjunctive therapy. iNO80 did not affect mor-
tality or alter the rate of change of Ang-2 in this study; 
however, targeting the endothelium to improve out-
comes in severe malaria remains a viable strategy with 
broader implications for other life-threatening infections 
such as sepsis characterized by endothelial dysfunction. 
Alternative methods to increase NO bioavailability at 
the endothelial barrier (higher dose, donor molecules, 
route of delivery) deserve further investigation. Given 
the global burden of childhood malaria and the relatively 
high rate of morbidity and mortality despite treatment 
with anti-malarials, continued investigation of adjunctive 
therapy is warranted.
Abbreviations
AKI: acute kidney injury; Ang-2: angiopoietin-2; DSMB: data and safety moni-
toring board; ELISA: enzyme-linked immunosorbent assay; HRP2: histidine rich 
protein 2; HR: hazard ratio; iNO: inhaled nitric oxide; IQR: inter-quartile range; 
LME: linear mixed-effects; metHb: methaemoglobin; NO: nitric oxide; PE: para-
sitized erythrocyte; pLDH: parasite lactate dehydrogenase; WHO: World Health 
Organization; WPB: Weibel-Palade body.
Authors’ contributions
MH designed the trial, directly supervised trial conduct in Uganda, man-
aged trial patients and supervised trial participant medical care, collected 
the data, analysed the data, and wrote the manuscript. AC participated in 
the trial design, led the unblinded team (randomization, metHb monitor-
ing), supervised the administration of iNO, performed the assays for Ang-2, 
and critically reviewed the manuscript. ROO participated in study design, 
oversaw the trial and critically reviewed the manuscript. LH participated in 
the trial design, supervised the administration of iNO and critically reviewed 
the manuscript. CM supervised the administration of iNO and performed the 
assays for Ang-2. HK and SH performed the assays for Ang-2. SN participated 
in the trial design, supervised trial participant medical care and critically 
reviewed the manuscript. CJ participated in the trial design, and critically 
reviewed the manuscript. WCL participated in the trial design and critically 
reviewed the manuscript. KCK conceived the study, participated in the trial 
design and critically reviewed the manuscript. All authors read and approved 
the final manuscript.
Author details
1 3-588D Edmonton Clinic Health Academy, University of Alberta, 11405 87 
Ave NW, Edmonton, AB T6G 1C9, Canada. 2 Sandra Rotman Centre for Global 
Health, MaRS Centre, University of Toronto, 101 College St TMDT 10-360A, 
Toronto, ON M5G 1L7, Canada. 3 Global Health Uganda, Upper Paediatrics 
Additional file
Additional file 1. Sensitivity analyses and quality measures for clini-
cal trial “Inhaled nitric oxide as adjunctive therapy for severe malaria”. 
Description: Sensitivity analyses on the primary and secondary (mortality) 
endpoints are provided. Measures of the quality of blinding and quality of 
clinical care in the trial are described.
Office, Mulago Hospital, PO Box 33842, Plot 138, Upper Mawanda Road, 
Kawempe, Kampala, Uganda. 4 Applied Health Research Centre, St Michael’s 
Hospital, 250 Yonge St, 6th Floor, Toronto, ON M5T 3M7, Canada. 5 Johns 
Hopkins School of Public Health, International Vaccine Access Center, 615 N 
Wolfe St, Baltimore, MD 21205, USA. 6 Jinja Regional Referral Hospital, Plot 7, 
Nalufenya Road, Jinja, Uganda. 7 Department of Pediatrics, Indiana University, 
702 Barnhill Dr, Room 5900, Indianapolis, IN 46202, USA. 8 Division of Infectious 
Disease, University of British Columbia, Rm D433, HP East, Vancouver Hospital, 
2733 Heather Street, Vancouver, BC V5Z-3J5, Canada. 9 Department of Medi-
cine, University of Washington, 1959 NE Pacific Street, HSB RR-511, Box 356420, 
Seattle, WA  98195-6420, USA. 
Acknowledgements
We thank all the patients and their families, the medical superintendant of 
the Jinja Regional Referral Hospital, the many medical officers, nurses and 
research assistants that cared for the patients and collected study data; the 
Uganda National Council on Science and Technology, the Uganda National 
Drug Authority, and the Data and Safety Monitoring Board for trial oversight. 
This study was supported by the Sandra Rotman Centre for Global Health, 
the Canadian Institutes of Health Research (CIHR) MOP-244701, 13721 and 
136813 (KCK), Canada Research Chair in Molecular Parasitology (KCK), Canada 
Research Chair in Infectious Diseases and Inflammation (WCL), CIHR Clinician-
Scientist Training Award (MH), and a Postdoctoral Research Award (ALC). This 
work was also supported by kind donations from Kim Kertland, the Tesari 
Foundation, and Rotary International (K-W group). The funders had no role in 
study design, data collection, data analysis, data interpretation, writing of the 
report, or decision to submit the article for publication. The researchers are 
independent from the funders.
Competing interests
The authors declare they have no competing interests.
Received: 7 August 2015   Accepted: 21 October 2015
References
 1. Murray CJ, Rosenfeld LC, Lim SS, Andrews KG, Foreman KJ, Haring D, et al. 
Global malaria mortality between 1980 and 2010: a systematic analysis. 
Lancet. 2012;379:413–31.
 2. WHO. Malaria fact sheet. Geneva: World Health Organization. Available 
at: http://www.who.int/malaria/areas/high_risk_groups/children/en/. 
Accessed 7 Apr 2014.
 3. Kyu HH, Fernandez E. Artemisinin derivatives versus quinine for cerebral 
malaria in African children: a systematic review. Bull World Health Organ. 
2009;87:896–904.
 4. Hawkes M, Opoka RO, Namasopo S, Miller C, Conroy AL, Serghides L, et al. 
Nitric oxide for the adjunctive treatment of severe malaria: hypothesis 
and rationale. Med Hypotheses. 2011;77:437–44.
 5. Serghides L, Kim H, Lu Z, Kain DC, Miller C, Francis RC, et al. Inhaled nitric 
oxide reduces endothelial activation and parasite accumulation in the 
brain, and enhances survival in experimental cerebral malaria. PLoS One. 
2011;6:e27714.
 6. Griffiths MJ, Evans TW. Inhaled nitric oxide therapy in adults. N Engl J 
Med. 2005;353:2683–95.
 7. Serirom S, Raharjo WH, Chotivanich K, Loareesuwan S, Kubes P, Ho M. 
Anti-adhesive effect of nitric oxide on Plasmodium falciparum cytoadher-
ence under flow. Am J Pathol. 2003;162:1651–60.
 8. Fiedler U, Scharpfenecker M, Koidl S, Hegen A, Grunow V, Schmidt JM, 
et al. The Tie-2 ligand angiopoietin-2 is stored in and rapidly released 
upon stimulation from endothelial cell Weibel-Palade bodies. Blood. 
2004;103:4150–6.
 9. Fiedler U, Reiss Y, Scharpfenecker M, Grunow V, Koidl S, Thurston G, et al. 
Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial 
role in the induction of inflammation. Nat Med. 2006;12:235–9.
 10. Conroy AL, Glover SJ, Hawkes M, Erdman LK, Seydel KB, Taylor TE, et al. 
Angiopoietin-2 levels are associated with retinopathy and predict mortal-
ity in Malawian children with cerebral malaria: a retrospective case-
control study. Crit Care Med. 2012;40:952–9.
Page 11 of 11Hawkes et al. Malar J  (2015) 14:421 
 11. Erdman LK, Dhabangi A, Musoke C, Conroy AL, Hawkes M, Higgins S, et al. 
Combinations of host biomarkers predict mortality among Ugandan 
children with severe malaria: a retrospective case-control study. PLoS 
One. 2011;6:e17440.
 12. Lovegrove FE, Tangpukdee N, Opoka RO, Lafferty EI, Rajwans N, Hawkes 
M, et al. Serum angiopoietin-1 and -2 levels discriminate cerebral malaria 
from uncomplicated malaria and predict clinical outcome in African 
children. PLoS One. 2009;4:e4912.
 13. Yeo TW, Lampah DA, Gitawati R, Tjitra E, Kenangalem E, Piera K, et al. Angi-
opoietin-2 is associated with decreased endothelial nitric oxide and poor 
clinical outcome in severe falciparum malaria. Proc Natl Acad Sci USA. 
2008;105:17097–102.
 14. Matsushita K, Morrell CN, Cambien B, Yang SX, Yamakuchi M, Bao C, et al. 
Nitric oxide regulates exocytosis by S-nitrosylation of N-ethylmaleimide-
sensitive factor. Cell. 2003;115:139–50.
 15. Anstey NM, Weinberg JB, Hassanali MY, Mwaikambo ED, Manyenga 
D, Misukonis MA, et al. Nitric oxide in Tanzanian children with malaria: 
inverse relationship between malaria severity and nitric oxide produc-
tion/nitric oxide synthase type 2 expression. J Exp Med. 1996;184:557–67.
 16. Lopansri BK, Anstey NM, Weinberg JB, Stoddard GJ, Hobbs MR, Levesque 
MC, et al. Low plasma arginine concentrations in children with cerebral 
malaria and decreased nitric oxide production. Lancet. 2003;361:676–8.
 17. Yeo TW, Lampah DA, Gitawati R, Tjitra E, Kenangalem E, McNeil YR, 
et al. Impaired nitric oxide bioavailability and l-arginine reversible 
endothelial dysfunction in adults with falciparum malaria. J Exp Med. 
2007;204:2693–704.
 18. Gramaglia I, Sobolewski P, Meays D, Contreras R, Nolan JP, Frangos JA, 
et al. Low nitric oxide bioavailability contributes to the genesis of experi-
mental cerebral malaria. Nat Med. 2006;12:1417–22.
 19. Finer NN, Barrington KJ. Nitric oxide for respiratory failure in infants born 
at or near term. Cochrane Database Syst Rev 2006;CD000399.
 20. Sokol J, Jacobs SE, Bohn D. Inhaled nitric oxide for acute hypoxemic res-
piratory failure in children and adults. Cochrane Database Syst Rev 2003; 
CD002787.
 21. Adhikari NK, Burns KE, Friedrich JO, Granton JT, Cook DJ, Meade MO. 
Effect of nitric oxide on oxygenation and mortality in acute lung injury: 
systematic review and meta-analysis. BMJ. 2007;334:779.
 22. Hawkes M, Opoka RO, Namasopo S, Miller C, Thorpe KE, Lavery JV, et al. 
Inhaled nitric oxide for the adjunctive therapy of severe malaria: protocol 
for a randomized controlled trial. Trials. 2011;12:176.
 23. Idro R, Aloyo J, Mayende L, Bitarakwate E, John CC, Kivumbi GW. Severe 
malaria in children in areas with low, moderate and high transmission 
intensity in Uganda. Trop Med Int Health. 2006;11:115–24.
 24. Hawkes M, Conroy AL, Opoka RO, Namasopo S, Liles WC, John CC, et al. 
Use of a three-band HRP2/pLDH combination rapid diagnostic test 
increases diagnostic specificity for falciparum malaria in Ugandan chil-
dren. Malar J. 2014;13:43.
 25. Dondorp AM, Fanello CI, Hendriksen IC, Gomes E, Seni A, Chhaganlal KD, 
et al. Artesunate versus quinine in the treatment of severe falciparum 
malaria in African children (AQUAMAT): an open-label, randomised trial. 
Lancet. 2010;376:1647–57.
 26. Hawkes M, Conroy AL, Opoka RO, Namasopo S, Liles WC, John CC, et al. 
Performance of point-of-care diagnostics for glucose, lactate, and hemo-
globin in the management of severe malaria in a resource-constrained 
hospital in Uganda. Am J Trop Med Hyg. 2014;90:605–8.
 27. Little RJ, D’Agostino R, Cohen ML, Dickersin K, Emerson SS, Farrar JT, et al. 
The prevention and treatment of missing data in clinical trials. N Engl J 
Med. 2012;367:1355–60.
 28. Conroy AL, Lafferty EI, Lovegrove FE, Krudsood S, Tangpukdee N, Liles 
WC, et al. Whole blood angiopoietin-1 and -2 levels discriminate cerebral 
and severe (non-cerebral) malaria from uncomplicated malaria. Malar J. 
2009;8:295.
 29. Erdman LK, Dhabangi A, Musoke C, Conroy AL, Hawkes M, Higgins S, et al. 
Combinations of host biomarkers predict mortality among Ugandan 
children with severe malaria: a retrospective case-control study. PLoS 
One. 2011;6:e17440.
 30. Idro R, Aloyo J. Manifestations, quality of emergency care and outcome of 
severe malaria in Mulago Hospital, Uganda. Afr Health Sci. 2004;4:50–7.
 31. Wraight WM, Young JD. Renal effects of inhaled nitric oxide in humans. Br 
J Anaesth. 2001;86:267–9.
 32. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, et al. 
Acute kidney injury network: report of an initiative to improve outcomes 
in acute kidney injury. Crit Care. 2007;11:R31.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
